<DOC>
	<DOCNO>NCT01721252</DOCNO>
	<brief_summary>The aim study determine prospectively value recently identify proteomic signature identify patient lung cancer , likely benefit respond favourably erlotinib therapy . This prospective study serum proteomics predictor response erlotinib therapy .</brief_summary>
	<brief_title>Tarceva . ICORG 08-41</brief_title>
	<detailed_description>Screening/Baseline 1 . Routine blood test ( Haematology Biochemistry ) per hospital practice 2 . Research serum sample proteomic study ( 10ml blood sample ) 3 . Routine pre-treatment CT formal RECIST/WHO measurements tumour size 2 month Post Commencement Treatment erlotinib : Routine CT RECIST/WHO assessment 4 month Post Commencement Treatment erlotinib : Routine CT RECIST/WHO assessment 1 year Post Commencement Treatment erlotinib ( per current standard care ) : Routine CT RECIST/WHO assessment Response Assessment : CT scan baseline , 2 4 month post commencement therapy one year treatment erlotinib analyzed emphasis identification disease progression . Follow Up : Subsequent follow-up per routine .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>18 year age older Any patient suit receive CT scan part his/her routine care Ability understand willingness sign write informed consent , give accord ICH/GCP , national/local regulation . A sign informed consent must obtain prior study specific procedure Planned treatment erlotinib . Patients young 18 year age Patients foreseen receive TarcevaTM treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>TarcevaTM</keyword>
	<keyword>proteomic signature</keyword>
</DOC>